Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2015 4,80 M
EBIT 2015 -23,0 M
Net income 2015 -24,5 M
Debt 2015 25,0 M
Yield 2015 -
Sales 2016 17,5 M
EBIT 2016 -12,8 M
Net income 2016 -14,1 M
Debt 2016 12,1 M
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016
EV / Sales 2015 30,2x
EV / Sales 2016 7,54x
Capitalization 120 M
More Financials
Company
Onxeo SA engages in the development of drugs for the treatment of cancer.The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP.It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad.The company was... 
Sector
Pharmaceuticals
Calendar
02/26Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
01/25 ONXEO ANNOUNCES EVOLUTION AND REINFO : udvider og styrker bestyrelsen (ONXEO ANN..
2015 ONXEO : PUBLICATION OF SHAREHOLDERS LETTER // DANISH TRANSLATION: Offentliggørel..
2015 ONXEO ANNOUNCES ITS FINANCIAL CALEND : offentliggør selskabets finanskalendar fo..
2015 SPECTRUM PHARMACEUTICALS : and Onxeo Announce Complete Response in 67% of Patien..
2015 ONXEO : Patent Issued for Treating Inflammation and Inflammatory Pain in Mucosa ..
2015 Interim Report 2015-01-01 - 2015-09-30
2015 ONXEO INITIATES COMPREHENSIVE STRATE : indleder omfattende strategiplan for at ø..
2015 ONXEO : Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combin..
More news
Sector news : Pharmaceuticals - NEC
09:32a PFIZER : Groton's 2015 grand list declines .8 percent
02/05 SANOFI : Muzammil Mansuri is Sanofi’s new Executive Committee member
02/05 SANOFI : Zealand clarifies its role in US patent litigation relating to lixisena..
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions